HC Wainwright Estimates uniQure’s Q3 Earnings (NASDAQ:QURE)

uniQure N.V. (NASDAQ:QURE) – HC Wainwright dropped their Q3 2026 earnings estimates for uniQure in a research note issued to investors on Thursday, July 30th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings of ($0.90) per share for the quarter, down from their prior estimate of ($0.84). HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2026 earnings at ($1.00) EPS, FY2026 earnings at ($3.98) EPS, Q1 2027 earnings at ($1.04) EPS, Q2 2027 earnings at ($1.07) EPS, Q3 2027 earnings at ($0.95) EPS, Q4 2027 earnings at ($0.81) EPS, FY2027 earnings at ($3.87) EPS, FY2028 earnings at ($1.07) EPS, FY2029 earnings at $1.95 EPS and FY2030 earnings at $5.07 EPS.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.40). uniQure had a negative net margin of 1,350.73% and a negative return on equity of 111.96%. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $5.45 million. During the same quarter in the prior year, the company earned ($0.69) earnings per share.

Several other research firms also recently weighed in on QURE. Leerink Partners raised their price target on uniQure from $36.00 to $70.00 and gave the stock an “outperform” rating in a research report on Thursday, June 18th. Chardan Capital lifted their price objective on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. The Goldman Sachs Group boosted their target price on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. Wells Fargo & Company upped their target price on shares of uniQure from $60.00 to $75.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Cantor Fitzgerald raised shares of uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 price target on the stock in a research note on Wednesday, June 17th. Thirteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $65.00.

uniQure Price Performance

QURE stock opened at $43.68 on Monday. The stock’s 50 day moving average price is $38.26 and its 200 day moving average price is $26.58. The firm has a market cap of $3.03 billion, a P/E ratio of -10.89 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 10.01 and a current ratio of 10.01. uniQure has a 1 year low of $8.73 and a 1 year high of $71.50.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of QURE. Avoro Capital Advisors LLC boosted its position in shares of uniQure by 38.4% in the fourth quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock worth $147,170,000 after acquiring an additional 1,705,556 shares during the last quarter. State Street Corp raised its stake in uniQure by 123.8% during the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock worth $77,319,000 after purchasing an additional 1,787,033 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of uniQure by 155.3% in the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock valued at $70,226,000 after purchasing an additional 1,785,275 shares during the last quarter. Orbimed Advisors LLC grew its stake in shares of uniQure by 189.7% during the 1st quarter. Orbimed Advisors LLC now owns 2,136,149 shares of the biotechnology company’s stock valued at $34,926,000 after buying an additional 1,398,749 shares during the period. Finally, Franklin Resources Inc. increased its holdings in shares of uniQure by 23.9% during the 3rd quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after buying an additional 383,066 shares during the last quarter. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at uniQure

In related news, Director Jack Kaye sold 21,167 shares of the stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $46.44, for a total transaction of $982,995.48. Following the transaction, the director directly owned 25,996 shares in the company, valued at approximately $1,207,254.24. This represents a 44.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew C. Kapusta sold 164,429 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $44.32, for a total value of $7,287,493.28. Following the completion of the sale, the chief executive officer directly owned 558,810 shares in the company, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 433,229 shares of company stock worth $17,944,799. Company insiders own 4.65% of the company’s stock.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.